Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. The company was founded in 2009 and is based in Norwood, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-963-0100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.82 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions
What is Corbus Pharmaceuticals' stock symbol?
Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."
How were Corbus Pharmaceuticals' earnings last quarter?
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) issued its quarterly earnings results on Tuesday, March, 12th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.07. The biopharmaceutical company earned $1.93 million during the quarter, compared to analysts' expectations of $1.99 million. Corbus Pharmaceuticals had a negative net margin of 1,154.52% and a negative return on equity of 116.34%. View Corbus Pharmaceuticals' Earnings History.
When is Corbus Pharmaceuticals' next earnings date?
What price target have analysts set for CRBP?
5 Wall Street analysts have issued twelve-month price targets for Corbus Pharmaceuticals' stock. Their predictions range from $22.00 to $38.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $27.00 in the next year. This suggests a possible upside of 261.4% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.
What is the consensus analysts' recommendation for Corbus Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.
What are Wall Street analysts saying about Corbus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Corbus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. " (3/14/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $38 PT on Corbus following earnings reported as of 12/31/2018. Corbus has four programs (two in Phase 3) in development, with topline data readouts for systemic sclerosis (SSc; last patient could be enrolled in May, with NDA submission in late-2020) and cystic fibrosis potentially available in 2020. Throughout 2019, we expect the company could report longer-term data and make further announcements regarding future commercialization plans." (3/12/2019)
Has Corbus Pharmaceuticals been receiving favorable news coverage?
Media stories about CRBP stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Corbus Pharmaceuticals' key competitors?
Some companies that are related to Corbus Pharmaceuticals include Allakos (ALLK), Xencor (XNCR), Puma Biotechnology (PBYI), Myovant Sciences (MYOV), Pacira Pharmaceuticals (PCRX), Wave Life Sciences (WVE), Opko Health (OPK), Prestige Consumer Healthcare (PBH), Aimmune Therapeutics (AIMT), Clovis Oncology (CLVS), Innoviva (INVA), Corcept Therapeutics (CORT), Gossamer Bio (GOSS), Theravance Biopharma (TBPH) and Cambrex (CBM).
What other stocks do shareholders of Corbus Pharmaceuticals own?
Who are Corbus Pharmaceuticals' key executives?
Corbus Pharmaceuticals' management team includes the folowing people:
- Dr. Yuval Cohen, CEO & Director (Age 44)
- Dr. Mark A. Tepper, Co-Founder, Pres & Chief Scientific Officer (Age 62)
- Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 61)
- Dr. Barbara White, Chief Medical Officer (Age 69)
- Ted Jenkins, Sr. Director of Investor Relations & Communications
Who are Corbus Pharmaceuticals' major shareholders?
Corbus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.98%), ETF Managers Group LLC (6.91%), IFP Advisors Inc (2.81%), FMR LLC (2.47%), Northern Trust Corp (1.03%) and Geode Capital Management LLC (0.95%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, David P Hochman, John Kenneth Jenkins, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.
Which major investors are selling Corbus Pharmaceuticals stock?
CRBP stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Raymond James Financial Services Advisors Inc., Virtus ETF Advisers LLC, MetLife Investment Advisors LLC, Northern Trust Corp and Creative Planning. View Insider Buying and Selling for Corbus Pharmaceuticals.
Which major investors are buying Corbus Pharmaceuticals stock?
CRBP stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, D. E. Shaw & Co. Inc., IFP Advisors Inc, Millennium Management LLC, Raymond James & Associates, Alps Advisors Inc., Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, David P Hochman, John Kenneth Jenkins, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.
How do I buy shares of Corbus Pharmaceuticals?
Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corbus Pharmaceuticals' stock price today?
One share of CRBP stock can currently be purchased for approximately $7.47.
How big of a company is Corbus Pharmaceuticals?
Corbus Pharmaceuticals has a market capitalization of $481.03 million and generates $4.82 million in revenue each year. The biopharmaceutical company earns $-55,670,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.
What is Corbus Pharmaceuticals' official website?
How can I contact Corbus Pharmaceuticals?
Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]
MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
